Predicting the Success of HPV Vaccines

October 25, 2005
Pharmaceutical Executive
Volume 0, Issue 0

Will vaccines against cervical cancer be the blockbusters that Merck and GSK are predicting? Or will issues of cost-effectiveness and parental reluctance hold them back? The experts weigh in on the debate.